Literature DB >> 1548774

Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies.

H Ghiasi1, R Kaiwar, A B Nesburn, S L Wechsler.   

Abstract

We have constructed a recombinant baculovirus expressing the herpes simplex virus type 1 (HSV-1) glycoprotein I (gI). Sf9 cells infected with this recombinant virus synthesized gI-related polypeptides with apparent molecular sizes of 52 and 56 kDa. The recombinant gI appeared to be glycosylated, since it was susceptible to both tunicamycin and endoglycosidase H, and the expressed gI was transported to the surface of infected cells as judged by indirect immunofluorescence. Antibodies to the recombinant gI raised in mice neutralized HSV-1 infectivity. Finally, we show here for the first time that vaccination with gI can protect mice against HSV-1 challenge.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1548774      PMCID: PMC289047     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Membrane proteins specified by herpes simplex viruses. V. Identification of an Fc-binding glycoprotein.

Authors:  R B Baucke; P G Spear
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Identification of a new glycoprotein of herpes simplex virus type 1 and genetic mapping of the gene that codes for it.

Authors:  D D Richman; A Buckmaster; S Bell; C Hodgman; A C Minson
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

3.  Location of the structural genes for glycoproteins gD and gE and for other polypeptides in the S component of herpes simplex virus type 1 DNA.

Authors:  G T Lee; M F Para; P G Spear
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

4.  Identification and characterization of a herpes simplex virus gene product required for encapsidation of virus DNA.

Authors:  V G Preston; J A Coates; F J Rixon
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

5.  Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants.

Authors:  B A Blacklaws; S Krishna; A C Minson; A A Nash
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

6.  Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins.

Authors:  Y Matsuura; R D Possee; H A Overton; D H Bishop
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

7.  Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus-infected cells.

Authors:  H Ghiasi; A B Nesburn; S L Wechsler
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

8.  Glycoprotein gE of herpes simplex virus type 1: effects of anti-gE on virion infectivity and on virus-induced fc-binding receptors.

Authors:  M F Para; R B Baucke; P G Spear
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

9.  Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI.

Authors:  D C Johnson; M C Frame; M W Ligas; A M Cross; N D Stow
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  The herpes simplex virus type 1 US7 gene product is a 66K glycoprotein and is a target for complement-dependent virus neutralization.

Authors:  V Sullivan; G L Smith
Journal:  J Gen Virol       Date:  1988-04       Impact factor: 3.891

View more
  8 in total

1.  Cloning and expression of the HN gene from the velogenic viscerotropic Newcastle disease virus strain AF2240 in Sf9 insect cells.

Authors:  H K Ong; A M Ali; A R Omar; K Yusoff
Journal:  Cytotechnology       Date:  2000-03       Impact factor: 2.058

2.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits.

Authors:  A B Nesburn; R L Burke; H Ghiasi; S Slanina; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus.

Authors:  D N Love; C W Bell; D Pye; S Edwards; M Hayden; G L Lawrence; D Boyle; T Pye; J M Whalley
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K.

Authors:  H Ghiasi; S Slanina; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

6.  Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice.

Authors:  H Ghiasi; R Kaiwar; A B Nesburn; S Slanina; S L Wechsler
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

7.  Overexpression of herpes simplex virus glycoprotein K (gK) alters expression of HSV receptors in ocularly-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-15       Impact factor: 4.799

Review 8.  Role of Herpes Simplex Virus Type 1 (HSV-1) Glycoprotein K (gK) Pathogenic CD8+ T Cells in Exacerbation of Eye Disease.

Authors:  Ujjaldeep Jaggi; Shaohui Wang; Kati Tormanen; Harry Matundan; Alexander V Ljubimov; Homayon Ghiasi
Journal:  Front Immunol       Date:  2018-12-07       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.